HISTORICAL BACKGROUND {#sec1-1}
=====================

The treatment for Wilms' tumor has a long tradition of the multicenter studies. First, the National Wilms' Tumor Study (NWTS) launched the Pan-American study on this malignancy in 1969. Shortly later, International Society of Paediatric Oncology (SIOP) in Europe started an international cooperation in this field (1971).\[[@ref1]\]

Both groups had similar aims, but tried to reach them in different ways. NWTS since its beginning advocated primary surgery whenever possible and the treatment related and adapted to the pathological postsurgical findings.\[[@ref1]\] SIOP noticed that the intraoperative tumor rupture rate at that time was approximately 30% and tried to find a way to downstage the disease preoperatively and make surgery easier and decrease the rate of this main intraoperative complication. The first attempt searching for a method meeting these aims compared in the trial was the preoperative radiotherapy versus primary surgery (SIOP 1, 1971-1974). The intraoperative rupture rate in the preoperatively irradiated patients was 4% and stage I rate 31%, whereas in the primarily operated on was32 and 14%, respectively.\[[@ref2]\] It had become clear that the preoperative radiotherapy downstages the disease and prevents the intraoperative tumor rupture. SIOP2 (1974-1976) confirmed this finding also for so-called small tumors. In this category of patients the intraoperative tumor rupture rate after radiotherapy fall dawn to 5% and in the primarily operated on remained high (20%).\[[@ref1]\]

At that time it was already known, that radiotherapy shall be avoided the more, the younger is a child. Consequently, the next SIOP study (SIOP5, 1977-1979), also built as a trial, compared preoperative radiotherapy and preoperative chemotherapy and evidenced the equal efficacy of both these methods in preventing the tumor rupture and downstaging the disease. The first objective looked was solved: The preoperative chemotherapy with vincristine and actinomycin D given for 4 weeks markedly prevented Wilms' tumor rupture and downstaged the disease.\[[@ref1][@ref3]\]

Continuing this way, SIOP was wondering whether a longer pretreatment could be even more effective in decreasing the intraoperative tumor rupture rate and improving the stage distribution. The SIOP9Trial and Study (1987-1991) started to compare 4-week vs 8-week schedules both with the same drugs and same schedule of administration (vincristine weekly and actinomycin D biweekly). Surprisingly, no further significant downstaging of the disease or a decrease in the intraoperative tumor rupture rate were observed. Also the survival curves were not different. For SIOP, it was argued to accept this 4-week preoperative chemotherapy as a "gold standard" for all patients aged more than 6 months at diagnosis with localized nephroblastoma.\[[@ref4][@ref5]\]

The treatment of patients staged IV (metastatic disease) and V (bilateral nephroblastoma) followed similar policy. The first group constitutes of approximately 12% of all the patients, the second one - 5%. In stage IV it was suggested to administer preoperatively three drugs (vincristine, actinomycin D, and doxorubicine) for 6 weeks. This schedule of the pretreatment appeared very effective. The overall long-term outcome in patients achieving complete remission after chemotherapy (metastasis disappeared) and the primary tumor surgery and in those after successful metastasectomy on regressing lung metastasis reached 83%. Regarding stage V patients, pretreatment was expected to lead to anephron-sparing surgery on at least one side leaving enough functional renal tissue. However, a very long preoperative chemotherapy seemed not to bring continuous effect. Nine to 12 weeks seemed adequate. Only very few cases required bilateral total nephrectomy and in more than 25% of patients bilateral nephron-sparing resections appeared possible with the same outcome as in case of one-sided total nephrectomy and nephron-sparing resection on the opposite side. Of course such comparisons must be made very carefully; the cases were selected according to tumor location within the kidney, response to chemotherapy, and the operating surgeon\'s opinion. It indicates that the results were both case- and surgeon-dependent. Anyway, currently, an attempt to bilateral partial nephrectomy in stage V patients is strongly suggested. Usually easier side shall be operated on first. After the easier side is operated on and the kidney resumed the function correctly, the child is operated on the more difficult tumor. The interval between the sessions is usually 2-3 weeks. One course of chemotherapy is recommended during this time. This approach helps avoiding perioperative dialysis following one-session bilateral resections when the kidneys may not resume sufficient function immediately.\[[@ref1][@ref6][@ref7][@ref8][@ref9]\]

SIOP also explored the question of postoperative treatment; however, this aspect seems less important for surgery. The studies SIOP1, 2, and 5 were dealing with the duration of postoperative chemotherapy and the value of anthracyclines and postoperative radiotherapy in stage II and III patients (SIOP 6, 1980-1987). The use of anthracyclines improved the outcome for stage II (lymph nodes invaded = N+) in stage III cases, but rather not in stages II (with the lymph nodes free of tumor = N-). Although the results were importantat the time of those trials, several factors have changed and cannot serve as a definite indication for treatment at present. Anyway, all brought a lot of new understanding and explored the way to go.\[[@ref10]\]

Recent protocols (SIOP 9301, 1993-2001) tried to adopt the aggressiveness of treatment to the real risk of the therapy failure. In this view, the preoperative chemotherapy offers an important selection value in terms of both the anatomical extension of the disease (change in the tumor volume) and, if applicable, also in the number and size of metastasis and its histological appearance. The tumors responding well to chemotherapy with high rate of necrosis had very good prognosis. In case of completely necrotic nephroblastoma, the overall survival reached 100% in case of stage I even if the postoperative treatment was omitted. On the other hand, high proportion of blastema surviving the preoperative chemotherapy implied prognosis almost as poor as anaplasia.\[[@ref11][@ref12][@ref13][@ref14]\]

Next study (SIOP 2001) changed the histopathological risk-grouping, taking into account these observations and asked again the question of the value of anthracyclines in the intermediate risk stage II and III patients on one hand, and decreasing the postoperative therapy in low riskgroup on the other.

Current study {#sec2-1}
-------------

Currently, SIOP Renal Tumor Study Group (RTSG) leads the SIOP 2001 study. It is based on the experience gained in the previous trials, proposes however new classification of histological risk groups and modified staging. Like in the previous studies, both factors are assessed after the preoperative chemotherapy. This pretreatment plays important role in stratifying patients to low risk (good responders; e.g., 100% necrotic), high risk (poorly responding; e.g., blastemal predominant or anaplastic), or intermediate risk (most common). This study asks randomized questions on whether the anthracyclines are necessary in the treatment of stage II and III intermediate risk histology Wilms tumor patients. The preliminary answer seems to suggest that the anthracyclines can be avoided in this group of children.\[[@ref1][@ref15]\]

Outlook of the study {#sec2-2}
--------------------

All patients with renal tumors aged less than 18 years could be included in this multicenter international study. The diagnosis of the primary tumor is based on the ultrasound imaging; however, majority of patients also had CT and, more recently, also MRI. The lung metastasis was considered clinically important only if seen on the classical chest X-ray. In case of doubt on diagnosis, a fine-needle aspiration or Tru-Cut biopsy are allowed and do not imply any upstaging. Once the diagnosis is established, children follow one of the three ways:

Unilateral localized cases received 4-week pretreatment with vincristine (weekly) andactinomycin D (biweekly)Metastatic patients --- 6 weeks of vincristine-actinomycin D (like above) and doxorubicine on weeks 1 and 5Bilateral tumors-vincristine-actinomycin D for no longer than 9-12 weeks in some cases reinforced with doxorubicine.

Children aged less than 6 months with localized disease was submitted to primary surgery if only their tumors were considered resectable.

The detailed staging and the risk-grouping were performed at the time of surgery based on the pathology examination of the specimen. Further treatment was adapted to the clinical stage (at surgery) and histological risk group. The SIOP 2001 staging system and the histology risk grouping are cited in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. The treatment flowchart for localized cases is presented in [Table 3](#T3){ref-type="table"}. Stage IV patients followed more complicated rules, depending on both primary tumor and metastasis response and resectability \[[Table 4](#T4){ref-type="table"}\].\[[@ref1][@ref12]\]

###### 

The revised SIOP working classification of renal tumors of childhood (2001)\[[@ref1][@ref12]\]
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###### 

The SIOP 2001 clinical staging system\[[@ref1]\]
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###### 

The post-operative treatment for stages 1-3 \[[@ref1]\]
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###### 

Stage IV, post-operative treatment\[[@ref1]\]
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Patients with bilateral disease had individualized treatment; however, in the postoperative part it relied on the general recommendations for a specific local stages/risk groups.\[[@ref1]\]

Surgical remarks {#sec2-3}
----------------

Number of SIOP trials and studies were related to the surgical issues. Studies 1, 2, 5, and 9; as it was mentioned above; looked in the randomized manner for a way to prevent the intraoperative tumor rupture. The retrospective analysis revealed that not only the intraoperative tumor rupture became rare after the pretreatment, but also other surgery-related complications. The rate of these complications did not exceed 8% in the pretreated patients registered in the SIOP9 (including the intraoperative tumor ruptures), whereas NWTS-3 reported 19.8% of the surgery-related complications among primarily nephrectomized patients ignoring the intraoperative tumor ruptures.\[[@ref16][@ref17][@ref18]\]

Although SIOP strongly recommends classical open tumor-nephrectomy according to Ladd and Gross suggestions, several new questions arise. Other surgical questionswere related to nephron-sparing nephrectomies in unilateral patients and the role of the minimal invasive nephrectomy. Both, however not recommended, were occasionally performed in the SIOP patients. Nephron-sparing resection was performed only in 3% of patients with unilateral Wilms tumor. The outcome was excellent and the overall survival reached 100%. Basic problem even in patients well selected for nephron-sparing resection relates to the regional lymph node status. The lymph nodes positive for tumor imply radiotherapy which conflicts the benefits of leaving the part of the kidney which will have to be covered by the field of radiotherapy and most probably will turn fibrotic. On the other hand, the lymph nodes are positive in 5.5% of patients, but particularly rarely in tumors with the initial volume smaller than 300 ml.\[[@ref1][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26][@ref27]\]

Regarding minimal invasive nephrectomy, it seems to bring very limited benefit to the patients with nephroblastoma when compared with the classical open surgery. Laparotomy to extract the mass is always necessary, surgical technique is more difficult, and lymph nodes sampling uneasy. A series of patients operated this way were analyzed by within SIOP studies. Despite good outcome, these children had enough number of lymph nodes sampled only in minority. Minimal invasive nephrectomy and nephron-sparing nephrectomy shall not compete---definitely more benefit is associated with partial nephrectomy performed the classical way. Any of those new techniques should not be undertaken in case of risk of decreasing the chance for complete resection compared to the classical way.\[[@ref28][@ref29][@ref30][@ref31][@ref32]\]
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